David Maris

Some people follow the herd.
I never have.

I’ve spent over 25 years in healthcare and finance, but the moments I’m proudest of weren’t celebrated when they happened.

They were lonely.
Unpopular.
Correct.

I called the collapse of Elan, Biovail, and Valeant—while the Street was still cheering them on.
I called out Mylan’s EpiPen price hikes. That report led to Congressional hearings.
I was the first to say “Buy” on Allergan.
I helped take Alcon public at $35. It hit $185.

I chose Alza over Elan. Jazz over Sepracor. Allergan over Valeant. Botox over Daxxify.
I always chose honesty over banking fees.
And I slept well.

When a company tried to silence me with a $3.6 billion lawsuit, I didn’t fold.
I fought. I won.
The CEO stepped down.
Harvard Business School teaches that case now. And has each year for more than 10 years.

I’ve been the top-ranked analyst six times.
But being right when it matters most—especially when you're alone—means more.

This isn’t just about stocks.
It’s about character.
It’s about protecting other people’s money like it’s your mother’s.
Because sometimes, it is.

This work? It’s not flashy.
But it matters.
And I’m not done yet.

David Maris has more than 25+ years of Wall Street experience in healthcare and finance in a variety of roles, most notably as a six-time #1 Institutional Investor ranked healthcare equity research analyst, but also as a portfolio manager for a leading hedge fund, and a trusted and collaborative advisor to management teams and boards.

Maris is known for his thorough research and in-depth analysis of healthcare companies, their financials, and strategies as well as his keen understanding of the regulatory environment in the healthcare industry. David has been featured for his views on various healthcare-related topics in prominent media outlets including CNBC, The Wall Street Journal, The New York Times, STAT, Bloomberg, CBS Evening News, NBC Nightly News, Good Morning America, Smart Money (“Five Honest Analysts”), The Financial Times, The Los Angeles Times, and The Economist.

David is an experienced public company board member having served on the board of directors of Cosmo Pharmaceuticals, and Amphastar Pharmaceuticals.  He has expertise as a keynote speaker for numerous leading and emerging drug company management teams and boards, as well as several leading industry organizations. Memberships include the American Finance Association and National Association of Corporate Directors.